Serotonin and depression: The marketing of a myth

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Healy, David ^a  

^a Hergest Unit   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; KETAMINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; ANTIDEPRESSANT AGENT; SEROTONIN RECEPTOR;

CLINICAL TRIAL (TOPIC); DEPRESSION; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG MARKETING; DRUG POTENCY; EDITORIAL; HUMAN; IMPULSIVENESS; INTERPERSONAL COMMUNICATION; MEDICAL LITERATURE; MELANCHOLIA; PATIENT COUNSELING; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SEROTONIN BLOOD LEVEL; SEROTONINERGIC SYSTEM; THERAPEUTIC MISCONCEPTION; COST BENEFIT ANALYSIS; DRUG EFFECTS; ECONOMICS; SUICIDE;

ANTIDEPRESSIVE AGENTS; COST-BENEFIT ANALYSIS; DEPRESSION; HUMANS; RECEPTORS, SEROTONIN; SEROTONIN; SUICIDE;

EID: 84930678190     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h1771     Document Type: Editorial

References (21)

1. Ashcroft GW, Sharman DF. 5-Hydroxyindoles in human cerebrospinal fluids. Nature 1960; 186: 1050-1.
2. Ashcroft GW. The receptor enters psychiatry. In: Healy D, ed. The psychopharmacologists. Vol 3. Arnold, 2000: 189-200.
3. Danish University Antidepressant Group. Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicentre study. Psychopharmacology 1986; 90: 131-8.
4. Danish University Antidepressant Group. Paroxetine. A selective serotonin reuptake inhibitor showing better tolerance but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affective Disorders 1990; 18: 289-99.
5. Healy D. The antidepressant era. Harvard University Press, 1997.
6. Lader M. Psychopharmacology: Clinical and social. In: Healy D, ed. The psychopharmacologists. Vol 1. Chapman and Hall, 1996: 463-82.
7. Healy D. Let them eat Prozac. New York University Press, 2004.
8. Healy D. Unauthorized Freud. BMJ 1999; 318: 949.
9. Ross J. The mood cure. Penguin, 2002.
10. Andrews PW, Bharwani A, Lee KR, Fox M, Thomson JA. Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response. Neurosci Biobehav Rev 2015; 51: 164-88.
11. Boardman A, Healy D. Modeling suicide risk in affective disorders. Eur Psychiatry 2001; 16: 400-5.
12. Shorter E, Fink M. Endocrine psychiatry. Oxford University Press, 2010.
13. Healy D, Aldred G. Antidepressant drug use and the risk of suicide. Int Rev Psychiatry 2005; 17: 163-72.
14. Spence R, Roberts A, Ariti C, Bardsley M. Focus on: Antidepressant prescribing. Trends in the prescribing of antidepressants in primary care. Health Foundation, Nuffield Trust, 2014.
15. Berman RM, Capiello A, Anand A. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351-4.
16. Murrough JW. Ketamine as a novel antidepressant: From synapse to behavior. Clin Pharmacol Ther 2012; 91: 303-9.
17. Atigari OV, Healy D. Sustained antidepressant response to ketamine. BMJ Case Rep 2013. doi: 10.1136/bcr-2013-200370.
18. Cloninger CR. A systematic method for clinical description and classification of personality variants: A proposal. Arch Gen Psychiatry 1987; 44: 573-88.
19. Linnoila M, Virkkunen M. Aggression, suicidality and serotonin. J Clin Psychiatry 1992; 53(suppl): 46-51.
20. Montgomery DB, Roberts A, Green M, Bullock T, Baldwin D, Montgomery S. Lack of efficacy of fluoxetine in recurrent brief depression and suicide attempts. Eur Arch Psych Clin Neurosci 1994; 244: 211-5.
21. Delamothe T. Very like a fish. BMJ 2011; 343: D4918.